Sp-cAMPS

• Description:

  Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC50 of 40 μM[1][2][3].

• UNSPSC:

  12352005

• Target:

  Phosphodiesterase (PDE) ; PKA

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease; Stem Cell/Wnt; TGF-beta/Smad

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Metabolic Disease; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/sp-camps.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O[C@H]1[C@@H](O[C@@]2([H])[C@@]1([H])O[P@](OC2)(S)=O)N3C4=C(C(N)=NC=N4)N=C3

• Molecular Formula:

  C10H12N5O5PS

• Molecular Weight:

  345.27

• References & Citations:

  [1]Su H Hung, et al. A new nonhydrolyzable reactive cAMP analog, (Sp) -adenosine-3',5'-cyclic-S- (4-bromo-2,3-dioxobutyl) monophosphorothioate irreversibly inactivates human platelet cGMP-inhibited cAMP phosphodiesterase. Bioorg Chem. 2002 Feb;30 (1) :16-31.|[2]L Y Wang, et al. Regulation of kainate receptors by cAMP-dependent protein kinase and phosphatases. Science. 1991 Sep 6;253 (5024) :1132-5.|[3]Ronald Jäger, et al. Activation of PDE10 and PDE11 phosphodiesterases. J Biol Chem. 2012 Jan 6;287 (2) :1210-9.|[4]P A Connelly, et al. A study of the mechanism of glucagon-induced protein phosphorylation in isolated rat hepatocytes using (Sp) -cAMPS and (Rp) -cAMPS, the stimulatory and inhibitory diastereomers of adenosine cyclic 3',5'-phosphorothioate. J Biol Chem. 1987 Mar 25;262 (9) :4324-32.|[5]G Dominguez, et al. Rescuing prefrontal cAMP-CREB pathway reverses working memory deficits during withdrawal from prolonged alcohol exposure. Brain Struct Funct. 2016 Mar;221 (2) :865-77.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  PDE10; PDE3; PKA

• CAS Number:

  [71774-13-5]